Pharmadrug Inc.
LMLLF · OTC
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.08 | 0.17 | 0.02 | -0.29 |
| FCF Yield | 0.00% | -0.00% | -0.00% | 0.13% |
| EV / EBITDA | -137.13 | -161.85 | -54.56 | -297.25 |
| Quality | ||||
| ROIC | 159.29% | -65.51% | -122.40% | -95.85% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.00 | 0.00 | -0.20 | 0.05 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -100.00% | -100.00% | -100.00% |
| Free Cash Flow Growth | 0.00% | -388.83% | -101.08% | 114.60% |
| Safety | ||||
| Net Debt / EBITDA | -81.13 | -79.41 | -25.30 | -164.31 |
| Interest Coverage | -0.55 | -0.14 | -0.94 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 |